[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Helmy Eltoukhy, Co-CEO and director of Guardant Health (GH), filed a Form 4 reporting open-market sales of the company’s common stock on 09/09/2025. The filing shows two sale transactions: 294,723 shares sold at a weighted average price of $59.4447 and 5,277 shares sold at a weighted average price of $59.9346. After these sales the reported beneficial ownership was 2,128,776 shares and 2,123,499 shares, respectively. Footnotes state the larger block sold at prices ranging from $58.79 to $59.78 and the smaller block from $59.79 to $60.25, with a weighted average reported for each block.

The Form 4 is signed by an attorney-in-fact on behalf of Mr. Eltoukhy and contains no additional commentary, option transactions, or other derivative activity.

Positive

• Insider retains a substantial holding with reported beneficial ownership of 2,128,776 and 2,123,499 shares after the reported sales
• Filing provides weighted-average prices and explicit price ranges, enhancing transparency about the transactions

Negative

• Material open-market sales reported: 294,723 shares at a weighted average of $59.4447 and 5,277 shares at a weighted average of $59.9346
• Form does not indicate a 10b5-1 plan (the plan checkbox is not checked), so the filing gives no automated-plan context for the timing of the sales

Insights

Corporate Governance Expert

TL;DR: A senior insider sold a material block of shares but retains a multi-million share holding; disclosure is clear and routine.

The reported open-market sales on a single date by the Co-CEO and director are material in the sense of being non-trivial share disposals disclosed under Section 16. The filing provides weighted-average prices and explanatory ranges, satisfying standard disclosure norms. Retention of over 2.1 million shares after the transactions indicates the insider remains a significant shareholder. The filing lacks any indication that sales were pursuant to a Rule 10b5-1 plan; the form does not check the plan box.

Securities Analyst

TL;DR: Two reported sales totaling 299,...shares at roughly $59.45–$59.93; transaction details are precise but convey no operational signal.

The Form 4 quantifies the exact share amounts and weighted-average prices and includes footnotes with price ranges for multiple trades. There are no derivative transactions or amendments disclosed. From a market-impact perspective, the disclosure is actionable for transparency but does not include context such as purpose of sale. The clear numeric detail supports accurate modeling of insider activity without requiring further inference.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eltoukhy Helmy

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		S		294,723(1)	D	$59.4447	2,128,776	D
Common Stock	09/09/2025		S		5,277(2)	D	$59.9346	2,123,499	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.79 to $59.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.79 to $60.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Helmy Eltoukhy	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health (GH) insider Helmy Eltoukhy sell on 09/09/2025?

The Form 4 reports sales of 294,723 shares at a weighted average price of $59.4447 and 5,277 shares at a weighted average price of $59.9346 on 09/09/2025.

How many Guardant Health shares did Helmy Eltoukhy own after the reported sales?

The filing shows beneficial ownership of 2,128,776 shares following the larger sale and 2,123,499 shares following the smaller sale.

Were the sale prices for the shares reported as single prices or ranges?

Each sale reports a weighted average price and a footnote with the trade price ranges: the 294,723-share block traded between $58.79 and $59.78; the 5,277-share block traded between $59.79 and $60.25.

Was the sale executed under a Rule 10b5-1 trading plan according to the Form 4?

No. The Form 4 does not indicate that the transactions were made pursuant to a Rule 10b5-1 plan; the related checkbox is not marked.

Who signed the Form 4 for Helmy Eltoukhy?

The Form 4 is signed by John G. Saia, as attorney-in-fact for Helmy Eltoukhy, with signature dated 09/11/2025.